Journey Medical Q2 revenue rises 23% to $18.5 million on Emrosi sales growth

Reuters2026/08/12 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fortress Biotech unit Journey Medical posted Q2 2026 revenue of USD 18.5 million, up 23% year over year.
Emrosi revenue reached USD 8.1 million; total prescriptions rose to about 36,000 from about 30,000 in Q1 2026.
GAAP net loss narrowed to USD 312,000 from USD 3.8 million a year earlier; gross margin held at 67%.
Cash and cash equivalents totaled USD 25.6 million at June 30, 2026, up from USD 24.1 million at year-end 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Journey Medical Q2 revenue rises 23% to $18.5 million on Emrosi sales growth

You may also like

Crypto prices